Development of a Portable, Ultra-Rapid and Ultra-Sensitive Cell-Based Biosensor for the Direct Detection of the SARS-CoV-2 S1 Spike Protein Antigen
Development of a Portable, Ultra-Rapid and Ultra-Sensitive Cell-Based Biosensor for the Direct Detection of the SARS-CoV-2 S1 Spike Protein Antigen
复制标题
DOI：
10.3390/s20113121
复制
发表时间：
2020-06-01
期刊：
影响因子：
3.9
通讯作者：
Kintzios, Spyridon
中科院分区：
文献类型：
--
作者：
Mavrikou, Sophie;Moschopoulou, Georgia;Kintzios, Spyridon
近期COVID-19大流行的关键挑战之一是准确估计感染者人数的能力，特别是无症状和/或早期患者。我们在此报告的概念验证的生物传感器的发展，能够检测SARS-CoV-2的S1刺突蛋白的病毒表面上表达。该生物传感器是基于膜工程哺乳动物细胞携带的人嵌合刺突S1抗体。我们证明，蛋白质的膜结合抗体的附着导致在一个选择性的和相当大的变化，通过生物电识别测定测量的细胞生物电特性。该新型生物传感器以超快速的方式（3分钟）提供结果，检测限为1 fg/mL，半线性响应范围为10 fg和1 μ g/mL。此外，未观察到与SARS-CoV-2核衣壳蛋白的交叉反应性。此外，生物传感器被配置为即用型平台，包括通过智能手机/平板电脑操作的便携式读出设备。通过这种方式，我们证明了这种新型生物传感器可以潜在地应用于SARS-CoV-2表面抗原的大规模筛查，而无需事先进行样品处理，从而为全球冠状病毒大流行的及时监测和最终控制提供了一种可能的解决方案。
One of the key challenges of the recent COVID-19 pandemic is the ability to accurately estimate the number of infected individuals, particularly asymptomatic and/or early-stage patients. We herewith report the proof-of-concept development of a biosensor able to detect the SARS-CoV-2 S1 spike protein expressed on the surface of the virus. The biosensor is based on membrane-engineered mammalian cells bearing the human chimeric spike S1 antibody. We demonstrate that the attachment of the protein to the membrane-bound antibodies resulted in a selective and considerable change in the cellular bioelectric properties measured by means of a Bioelectric Recognition Assay. The novel biosensor provided results in an ultra-rapid manner (3 min), with a detection limit of 1 fg/mL and a semi-linear range of response between 10 fg and 1 mu g/mL. In addition, no cross-reactivity was observed against the SARS-CoV-2 nucleocapsid protein. Furthermore, the biosensor was configured as a ready-to-use platform, including a portable read-out device operated via smartphone/tablet. In this way, we demonstrate that the novel biosensor can be potentially applied for the mass screening of SARS-CoV-2 surface antigens without prior sample processing, therefore offering a possible solution for the timely monitoring and eventual control of the global coronavirus pandemic.